Here's who's calling the shots for the 2024 Houston Innovation Awards. Photos courtesy

Ten Houstonians are in the hot seat for deciding the best companies and individuals in Houston's innovation ecosystem.

InnovationMap has announced its 2024 Houston Innovation Awards judging panel, which includes startup founders, nonprofit leaders, investors, corporate innovators, and more. In addition to the 10 judges, InnovationMap Editor Natalie Harms will serve as the editorial representative on the judging panel.

The selected judges will evaluate applications from the nearly 300 nominations that were submitted this year. The judges will be using their expertise to evaluate the nominees' applications, which are due to InnovationMap this week.

Read about this year's judges below, and don't forget to secure your tickets to the November 14 event to see who the panel selects as the winners for the annual celebration of Houston innovation.



Angela Wilkins, chief data officer at Starling Medical

Houston data scientist joins medical device startup amid AI evolution in the sectorAngela Wilkins joins the Houston Innovators Podcast to discuss the intersection of data and health care. Photo courtesy

Angela Wilkins has had a decade-long career in data science in business and academia and now oversees data science for Houston health tech company Starling Medical. She founded Mercury Data Science, which became OmniScience, and previously ran Rice University's Ken Kennedy Institute as executive director.

Brad Burke, associate vice president for industry and new ventures at Rice University's Office of Innovation and executive director of the Rice Alliance

The 2023 recipient of the Trailblazer Award, Brad Burke returns to the Houston Innovation Awards as a judge. For over 20 years, he's led the Rice Alliance for Technology and Entrepreneurship, and recently took on a new leadership role within the university's growing Office of Innovation.

Calicia Johnson, senior product manager at Xbox and co-lead for Black at Xbox at Microsoft

Calicia Johnson is a leader within Microsoft's Houston office, especially when it comes to representing and encouraging diversity. She was named the winner of the 2023 DEI Champion award at the Houston Innovation Awards. Prior to Xbox, she worked for nearly 10 years in oil and gas with the bulk of that time at Chevron.

Emily Cisek, CEO and founder of The Postage

Last year, Emily Cisek's company, The Postage, a secure life planning and small business succession platform, was a finalist in three Houston Innovation Awards categories, winning the award for Female-Founded Business. She returns as a judge as her company continues to grow.

Grace Rodriguez, CEO and executive director of Impact Hub Houston

Grace Rodriguez was a judge for the inaugural Houston Innovation Awards in 2021, and she returns to judge the awards in accordance to her mission of helping "do gooders do greater." In addition to leading Impact Hub Houston, she is a board member of the City of Houston Office of Business Opportunity and is on the Board of Directors for Downtown Houston.

Joey Sanchez, founder of Cup of Joey

As the 2024 Ecosystem Builder award recipient, Joey Sanchez has worked for years leading Houston innovation, including as senior director of ecosystems at the Ion Houston and director of corporate engagement at Houston Exponential. He's now growing his startup, Cup of Joey, a weekly coffee meetup organization, across Houston.

Jon Nordby, managing partner at investment firm Anthropy Partners and founder of EconWerx

For years, Jon Nordby has been a champion of Houston innovation in his previous leadership roles at Houston Exponential, MassChallenge, and the Greater Houston Partnership. A former Houston Innovation Awards judge from 2021, he now works hands on with startups and organizations looking to grow an innovation ecosystem.

Margarita Kelrikh, counsel at Pillsbury

As counsel in Pillsbury's Houston office, Margarita Kelrikh has supported the firm's growing startup clients since her appointment earlier this year. Prior to joining the firm, she held in-house counsel positions at a few companies, including WeWork. She received her bachelor's degree at the University of Chicago and her law degree at Columbia School of Law.

Pedro Silva, co-founder of Milkify

Pedro Silva co-founded Milkify, a freeze-drying breastmilk service, with his wife, Berkley Luck, and the company has appeared on Shark Tank and won last year's BIPOC-Founded Business Award.

Wade Pinder, founder of Product Houston

As the 2023 Mentor of the Year winner, Wade Pinder has mentored countless Houston startups and has decades of experience in product development — most recently through his own company, Product Houston.

Editorial judge: Natalie Harms, editor of InnovationMap

For the fourth year, Natalie Harms will represent InnovationMap on the annual awards judging panel as the founding editor of InnovationMap the host of the Houston Innovators Podcast.

She reports on innovation and technology for InnovationMap and on energy transition for EnergyCapitalHTX — and their impact on the city of Houston. A Houston native, she's worked as a business journalist for almost a decade and has a degree in journalism from the University of Houston and a certificate in publishing from New York University.

This week's roundup of Houston innovators includes Angela Wilkins of Starling Medical, Sean Kelly of Amperon, and Laureen Meroueh of Hertha Metals. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with a health tech data scientist, a CEO celebrating an international expansion, and a founder who won a big DOE prize.

Angela Wilkins, chief data scientist at Starling Medical

Angela Wilkins joins the Houston Innovators Podcast to discuss the intersection of data and health care. Photo courtesy

When most people hear about Houston startup Starling Medical, they might think about how much potential the medical device company has in the field of urinalysis diagnostics. But that's not quite where Angela Wilkins's head went.

Wilkins explains on the Houston Innovators Podcast that when she met the company's co-founders, Hannah McKenney and Drew Hendricks, she recognized them as very promising startup leaders taking action on a real health care problem. Starling's device can collect urine and run diagnostics right from a patient's toilet.

"It was one of those things where I just thought, 'They're going to get a bunch of data soon,'" Wilkins says. "The opportunity is just there, and I was really excited to come on and build their AI platform and the way they are going to look at data."

For about a year, Wilkins supported the startup as an adviser. Now, she's working more hands on as chief data officer as the company grows. Read more.

Sean Kelly, CEO and co-founder of Amperon

Amperon officially expanded in Europe. Photo via LinkedIn

Houston-based, AI-powered electricity forecasting and analytics services company Amperon Holdings is live in Europe. The expansion, which Co-Founder and CEO Sean Kelly previously told InnovationMap about, is official, the company announced this month. In addition to the expansion, Amperon announced Jon Ecker as general manager, Europe, and Kelsey Hultberg as executive vice president, communications, and chief of staff.

Now, European companies that buy and sell energy in the renewable energy producers, financial institutions, and utilities markets can leverage Amperon's platform of AI and machine learning technologies to access short- and long-term forecasts for their individual meters and generation assets.

“As a warmer-than-expected June ushers in a hot summer, and increasing uncertainty looms for the calmer fall months due to the influx of wind and solar generation, we are eager to assist our European customers in navigating the power market volatility caused by heat waves, extreme weather events, and shifts in power usage across the region,” Kelly says in a news release. Read more.

Laureen Meroueh, founder of Hertha Metals

Hertha Metals, based in Conroe, won first place at the 2024 Summer Energy Program for Innovation Clusters (EPIC) Startup Pitch Competition. Photo via LinkedIn

Four startups from across the country won over $160,000 in cash prizes from the U.S. Department of Energy’s Office of Technology Transitions earlier this month, and a Houston-area company claimed the top prize.

Hertha Metals, based in Conroe, won first place at the 2024 Summer Energy Program for Innovation Clusters (EPIC) Startup Pitch Competition. The program honors and supports clean energy innovators nominated by clean technology business incubators.

Hertha Metals was founded by Laureen Meroueh, a mechanical engineer and materials scientist, in 2022. Read more.

Angela Wilkins joins the Houston Innovators Podcast to discuss the intersection of data and health care. Photo courtesy

Houston data scientist joins medical device startup amid AI evolution in the sector

HOUSTON INNOVATORS PODCAST EPISODE 241

When most people hear about Houston startup Starling Medical, they might think about how much potential the medical device company has in the field of urinalysis diagnostics. But that's not quite where Angela Wilkins's head went.

Wilkins explains on the Houston Innovators Podcast that when she met the company's co-founders, Hannah McKenney and Drew Hendricks, she recognized them as very promising startup leaders taking action on a real health care problem. Starling's device can collect urine and run diagnostics right from a patient's toilet.

"It was one of those things where I just thought, 'They're going to get a bunch of data soon,'" Wilkins says. "The opportunity is just there, and I was really excited to come on and build their AI platform and the way they are going to look at data."

For about a year, Wilkins supported the startup as an adviser. Now, she's working more hands on as chief data officer as the company grows.



Wilkins, who serves as a mentor and adviser for several startups, has a 20-year career in Houston across all sides of the innovation equation, working first at Baylor College of Medicine before co-founding Mercury Data Science — now OmniScience. Most recently she served as executive director of the Ken Kennedy Institute at Rice University.

This variety in her resume makes her super connective — a benefit to all the startups she works with, she explains. The decision to transition to a startup team means she gets to work hands on in building a technology — while bringing in her experience from other institutions.

"I think I've really learned how to partner with those institutions," she says on the show. "I've really learned how to make those bridges, and that's a big challenge that startups face."

"When we talk about the Houston innovation ecosystem, it's something we should be doing better at because we have so many startups and so many places that would like to use better technology to solve problems," she continues.

Wilkins has data and artificial intelligence on the mind in everything she does, and she even serves on a committee at the state level to learn and provide feedback on how Texas should be regulating AI.

"At the end of the day, the mission is to put together a report and strategy on how we think Texas should think about AI," she explains. "It's beyond just using an algorithm, they need infrastructure."

Colorado is the first state to pass legislation surrounding AI, and Wilkins says all eyes are on how execution of that new law will go.

"We should have technology that can be double checked to make sure we're applying it in a way that's fair across all demographics. It's obvious that we should do that — it's just very hard," she says.

Veronica Wu, founder of First Bight Ventures, recently announced new team members and her hopes for making Houston a leader in synthetic biology. Photo courtesy of First Bight Ventures

Houston synthetic biology VC grows team ahead of foundry launch

future of tech

Since launching earlier this year, a Houston-based venture capital firm dedicated to investing in synthetic biology companies has made some big moves.

First Bight Ventures, founded by Veronica Wu, announced its growing team and plans to stand up a foundry and accelerator for its portfolio companies and other synthetic biology startups in Houston. The firm hopes to make Houston an international leader in synthetic biology.

“We have a moment in time where we can make Houston the global epicenter of synthetic biology and the bio economy," Wu says to a group of stakeholders last week at First Bight's Rocketing into the Bioeconomy event. "Whether its energy, semiconductor, space exploration, or winning the World Series — Houstonians lead. It’s in our DNA. While others look to the stars, we launch people into space.”

At First Bight's event, Wu introduced the company's new team members. Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University, joined First Bight as partner, and Serafina Lalany, former executive director of Houston Exponential, was named entrepreneur in residence. Carlos Estrada, who has held leadership positions within WeWork in Houston, also joins the team as entrepreneur in residence and will oversee the company's foundry and accelerator that will be established to support synthetic biology startups, Wu says.

“First Bight is investing to bring the best and the brightest — and most promising — synthetic biology startups from around the country to Houston," Wu continues.

First Bighthas one seed-staged company announced in its portfolio. San Diego-based Persephone Biosciences was founded in 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler and Steve Van Dien. The company is working on developing microbial products that impact patient and infant health.

Wu, who worked at Apple before the launch of the iPhone and Tesla before Elon Musk was a household name, says she saw what was happening in Houston after her brother moved to town. She first invested in Houston's synthetic biology ecosystem when she contributed to one of Solugen's fundraising rounds. The alternative plastics company is now a unicorn valued at over $1 billion.

“I founded First Bight because of what I see is the next great wave of technology innovation," she says at the event. "I founded it in Houston because the pieces are right here.”

This week's roundup of Houston innovators includes Erica Sinner of DanceKard, Angela Wilkins of Rice University, and Gina Luna of GP Capital Partners. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from dating tech to investment — recently making headlines in Houston innovation.

Erica Sinner, founder of DanceKard

Houston-based DanceKard is focused on getting singles off the endless swiping in order to make lasting connections and relationships. Photo courtesy of DanceKard

A proud Houstonian, Erica Sinner, whose background is in commercial real estate, was interested in creating a dating app that brought in local businesses. She launched DanceKard with several different offerings — all geared at driving in-person connections. Users can join the app to find events — not necessarily singles-specific events, although those are an option, but meetups where you know a certain number of singles will be in attendance.

"We focus a lot on group dating," Sinner explains. "That's something nobody does."

Singles, along with their single friends, can indicate on the app that they are interested in four, six, or eight-person dates, and see if their are other groups of friends looking to connect. Click here to read more.

Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University

"Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers." Photo courtesy

Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University, knows data and artificial intelligence can hold bias. It is, after all, designed by humans who have biases whether they know it or not. An issue with this is when these biases affect health care.

"AI presents the opportunity to bring greater personalization to healthcare, but it equally presents the risk of entrenching existing inequalities. We have the opportunity in front of us to take a considered approach to data collection, regulation, and use that will provide a fuller and fairer picture and enable the next steps for AI in healthcare," Wilkins writes in her guest column. Click here to read more.

Gina Luna, partner at GP Capital Partners

Gina Luna joins the Houston Innovators Podcast this week. Photo courtesy of Gina Luna

For most of Gina Luna's career, which includes two decades at JP Morgan before running her own strategic consulting firm, her bread and butter has been working with privately held, lower-middle market companies. Her latest endeavor is no different.

Luna — along with Paul Hobby, and Peter Shaper at Genesis Park — have joined forces to create GP Capital Partners, a new $275 million fund structured as a Small Business Investment Company. The fund will deploy funding into 20 to 25 companies within the region.

"The four of us just thought there was a real opportunity to bring this kind of capital to middle market companies in Houston, Texas, an the Gulf Coast region," Luna says on this week's episode of the Houston Innovators Podcast. "We have already seen, even in the relatively early days, there is a need an an opportunity to invest in great companies, and we are really excited to be doing that." Click here to read more and stream the podcast.

"Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers." Photo via UH.edu

Houston expert explains health care's inequity problem

guest column

We are currently in the midst of what some have called the "wild west" of AI. Though healthcare is one of the most heavily regulated sectors, the regulation of AI in this space is still in its infancy. The rules are being written as we speak. We are playing catch-up by learning how to reap the benefits these technologies offer while minimizing any potential harms once they've already been deployed.

AI systems in healthcare exacerbate existing inequities. We've seen this play out into real-world consequences from racial bias in the American justice system and credit scoring, to gender bias in resume screening applications. Programs that are designed to bring machine "objectivity" and ease to our systems end up reproducing and upholding biases with no means of accountability.

The algorithm itself is seldom the problem. It is often the data used to program the technology that merits concern. But this is about far more than ethics and fairness. Building AI tools that take account of the whole picture of healthcare is fundamental to creating solutions that work.

The Algorithm is Only as Good as the Data

By nature of our own human systems, datasets are almost always partial and rarely ever fair. As Linda Nordling comments in a Nature article, A fairer way forward for AI in healthcare, "this revolution hinges on the data that are available for these tools to learn from, and those data mirror the unequal health system we see today."

Take, for example, the finding that Black people in US emergency rooms are 40 percent less likely to receive pain medication than are white people, and Hispanic patients are 25 percent less likely. Now, imagine the dataset these findings are based on is used to train an algorithm for an AI tool that would be used to help nurses determine if they should administer pain relief medication. These racial disparities would be reproduced and the implicit biases that uphold them would remain unquestioned, and worse, become automated.

We can attempt to improve these biases by removing the data we believe causes the bias in training, but there will still be hidden patterns that correlate with demographic data. An algorithm cannot take in the nuances of the full picture, it can only learn from patterns in the data it is presented with.

Bias Creep

Data bias creeps into healthcare in unexpected ways. Consider the fact that animal models used in laboratories across the world to discover and test new pain medications are almost entirely male. As a result, many medications, including pain medication, are not optimized for females. So, it makes sense that even common pain medications like ibuprofen and naproxen have been proven to be more effective in men than women and that women tend to experience worse side effects from pain medication than men do.

In reality, male rodents aren't perfect test subjects either. Studies have also shown that both female and male rodents' responses to pain levels differ depending on the sex of the human researcher present. The stress response elicited in rodents to the olfactory presence of a sole male researcher is enough to alter their responses to pain.

While this example may seem to be a departure from AI, it is in fact deeply connected — the current treatment choices we have access to were implicitly biased before the treatments ever made it to clinical trials. The challenge of AI equity is not a purely technical problem, but a very human one that begins with the choices that we make as scientists.

Unequal Data Leads to Unequal Benefits

In order for all of society to enjoy the many benefits that AI systems can bring to healthcare, all of society must be equally represented in the data used to train these systems. While this may sound straightforward, it's a tall order to fill.

Data from some populations don't always make it into training datasets. This can happen for a number of reasons. Some data may not be as accessible or it may not even be collected at all due to existing systemic challenges, such as a lack of access to digital technology or simply being deemed unimportant. Predictive models are created by categorizing data in a meaningful way. But because there's generally less of it, "minority" data tends to be an outlier in datasets and is often wiped out as spurious in order to create a cleaner model.

Data source matters because this detail unquestionably affects the outcome and interpretation of healthcare models. In sub-Saharan Africa, young women are diagnosed with breast cancer at a significantly higher rate. This reveals the need for AI tools and healthcare models tailored to this demographic group, as opposed to AI tools used to detect breast cancer that are only trained on mammograms from the Global North. Likewise, a growing body of work suggests that algorithms used to detect skin cancer tend to be less accurate for Black patients because they are trained mostly on images of light-skinned patients. The list goes on.

We are creating tools and systems that have the potential to revolutionize the healthcare sector, but the benefits of these developments will only reach those represented in the data.

So, what can be done?

Part of the challenge in getting bias out of data is that high volume, diverse and representative datasets are not easy to access. Training datasets that are publicly available tend to be extremely narrow, low-volume, and homogenous—they only capture a partial picture of society. At the same time, a wealth of diverse health data is captured every day in many healthcare settings, but data privacy laws make accessing these more voluminous and diverse datasets difficult.

Data protection is of course vital. Big Tech and governments do not have the best track record when it comes to the responsible use of data. However, if transparency, education, and consent for the sharing of medical data was more purposefully regulated, far more diverse and high-volume data sets could contribute to fairer representation across AI systems and result in better, more accurate results for AI-driven healthcare tools.

But data sharing and access is not a complete fix to healthcare's AI problem. Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers. At the end of the day, we want to teach our algorithms to make good choices but we are still figuring out what good choices should look like for ourselves.

AI presents the opportunity to bring greater personalization to healthcare, but it equally presents the risk of entrenching existing inequalities. We have the opportunity in front of us to take a considered approach to data collection, regulation, and use that will provide a fuller and fairer picture and enable the next steps for AI in healthcare.

------

Angela Wilkins is the executive director of the Ken Kennedy Institute at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.